NCT06697223View on ClinicalTrials.gov

A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated with the INTERCEPT Blood System for Platelets with LED Illuminator.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions
Healthy Subjects
Interventions
DEVICE

INTERCEPT Blood System for Platelets with LED Illuminator

Apheresis platelet components in 100% plasma collected using the Trima separator, prepared with the INTERCEPT Blood System for Platelets (Test Platelets) using the LED Illuminator and stored for 5 days at 20 to 24°C with continuous agitation.

Trial Locations (2)

23510

American Red Cross Research Laboratory, Norfolk

98102

Bloodworks Northwest Research Institute, Seattle

Sponsors

Lead Sponsor

Cerus Corporation
All Listed Sponsors
lead

Cerus Corporation

INDUSTRY

NCT06697223 - A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated with the INTERCEPT Blood System for Platelets with LED Illuminator. | Biotech Hunter | Biotech Hunter